BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 28178623)

  • 21. CCL21 as an independent favorable prognostic factor for stage III/IV colorectal cancer.
    Zou Y; Chen Y; Wu X; Yuan R; Cai Z; He X; Fan X; Wang L; Wu X; Lan P
    Oncol Rep; 2013 Aug; 30(2):659-66. PubMed ID: 23760102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
    Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
    BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues].
    Lin MX; Wen ZF; Feng ZY; He D
    Ai Zheng; 2008 Dec; 27(12):1321-6. PubMed ID: 19080002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer.
    Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Takahashi A; Kakuta M; Nishimura Y; Yamaguchi K
    J Surg Oncol; 2014 Dec; 110(8):982-8. PubMed ID: 25154726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy.
    Liang L; Zhu J; Jia H; Huang L; Li D; Li Q; Li X
    Oncotarget; 2016 Jan; 7(1):1014-28. PubMed ID: 26510910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance.
    Hu L; Chen HY; Han T; Yang GZ; Feng D; Qi CY; Gong H; Zhai YX; Cai QP; Gao CF
    Tumour Biol; 2016 Jan; 37(1):837-45. PubMed ID: 26254099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A molecular signature for the prediction of recurrence in colorectal cancer.
    Wang L; Shen X; Wang Z; Xiao X; Wei P; Wang Q; Ren F; Wang Y; Liu Z; Sheng W; Huang W; Zhou X; Du X
    Mol Cancer; 2015 Feb; 14(1):22. PubMed ID: 25645394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased expression of Rab5A predicts metastasis and poor prognosis in colorectal cancer patients.
    Yu MH; Luo Y; Qin SL; Zhong M
    Int J Clin Exp Pathol; 2015; 8(6):6974-80. PubMed ID: 26261586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laminin β3 expression as a prognostic factor and a predictive marker of chemoresistance in colorectal cancer.
    Fukazawa S; Shinto E; Tsuda H; Ueno H; Shikina A; Kajiwara Y; Yamamoto J; Hase K
    Jpn J Clin Oncol; 2015 Jun; 45(6):533-40. PubMed ID: 25770060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance.
    He S; Zhou H; Zhu X; Hu S; Fei M; Wan D; Gu W; Yang X; Shi D; Zhou J; Zhou J; Zhu Z; Wang L; Li D; Zhang Y
    Biomed Pharmacother; 2014 Jun; 68(5):507-13. PubMed ID: 24751002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer.
    Qu F; Chen Y; Wang X; He X; Ren T; Huang Q; Zhang J; Liu X; Guo X; Gu J; Xing J
    Carcinogenesis; 2015 May; 36(5):543-52. PubMed ID: 25823896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulated GAS1 expression correlates with recurrence in stage II and III colorectal cancer.
    Jiang Z; Xu Y; Cai S
    Hum Pathol; 2011 Mar; 42(3):361-8. PubMed ID: 21111449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of Pim-3 in colorectal cancer and its relationship with prognosis.
    Zhou Z; Zhang R; Wang R; Zhang Y; Xu L; Chen J; Zhang J; Huang Z; Chen M; Pan Z
    Tumour Biol; 2016 Jul; 37(7):9151-6. PubMed ID: 26768612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Elsaleh H; Iacopetta B
    Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
    Stachelscheid J; Jiang Q; Aszyk C; Warner K; Bley N; Müller T; Vydzhak O; Symeonidis K; Crispatzu G; Mayer P; Blakemore SJ; Goehring G; Newrzela S; Hippler S; Robrecht S; Kreuzer KA; Pallasch C; Krüger M; Lechner A; Fischer K; Stilgenbauer S; Beutner D; Hallek M; Auguin D; Hüttelmaier S; Bloehdorn J; Vasyutina E; Herling M
    Blood; 2023 Mar; 141(12):1425-1441. PubMed ID: 36179280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche.
    Xu X; Chang W; Yuan J; Han X; Tan X; Ding Y; Luo Y; Cai H; Liu Y; Gao X; Liu Q; Yu Y; Du Y; Wang H; Ma L; Wang J; Chen K; Ding Y; Fu C; Cao G
    Oncotarget; 2016 Jan; 7(1):798-813. PubMed ID: 26556874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor in CRC patients in the era of the RAS.
    Yanmaz MT; Demir G; Erdamar S; Keskin S; Aydin MF; Guner SI
    Hepatogastroenterology; 2015; 62(137):40-4. PubMed ID: 25911864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor deposit is a poor prognostic indicator for patients who have stage II and III colorectal cancer with fewer than 4 lymph node metastases but not for those with 4 or more.
    Nagayoshi K; Ueki T; Nishioka Y; Manabe T; Mizuuchi Y; Hirahashi M; Oda Y; Tanaka M
    Dis Colon Rectum; 2014 Apr; 57(4):467-74. PubMed ID: 24608303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.